The agency’s letter of support for using the α-synuclein seed amplification assay biomarker was supported by data observed in the Parkinson’s Progression Markers Initiative cohort study.:
Source: Neurology Read More
FDA Supports Alpha-Synuclein Seed Amplification Assay Biomarker for Clinical Trials in Parkinson Disease
Related Posts
<![CDATA[Novel Digital Measures for Tracking Disease
Progression in Duchenne Muscular Dystrophy Beyond Loss of
Ambulation]]>
<![CDATA[Novel Digital Measures for Tracking Disease Progression in Duchenne Muscular Dystrophy Beyond Loss of Ambulation]]>
